Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Free Cash Flow (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Free Cash Flow for 8 consecutive years, with -$15.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow fell 156.6% to -$15.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$73.4 million, a 52.01% decrease, with the full-year FY2024 number at -$58.7 million, up 31.81% from a year prior.
  • Free Cash Flow was -$15.3 million for Q3 2025 at Precision Biosciences, up from -$20.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $66.9 million in Q1 2021 to a low of -$33.0 million in Q2 2021.
  • A 5-year average of -$13.9 million and a median of -$20.3 million in 2025 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: skyrocketed 347.83% in 2021, then crashed 183.57% in 2023.
  • Precision Biosciences' Free Cash Flow stood at -$25.2 million in 2021, then increased by 10.76% to -$22.5 million in 2022, then surged by 62.64% to -$8.4 million in 2023, then plummeted by 123.65% to -$18.8 million in 2024, then grew by 18.69% to -$15.3 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Free Cash Flow are -$15.3 million (Q3 2025), -$20.3 million (Q2 2025), and -$19.1 million (Q1 2025).